Similar articles

• HER2 targeted therapy in breast cancer...beyond Herceptin.

  Pal SK, Pegram M. Pal SK, et al. Rev Endocr Metab Disord. 2007 Sep;8(3):269-77. doi: 10.1007/s11154-007-9040-6. Rev Endocr Metab Disord. 2007. PMID: 17899385 Review.
• Advances in HER2-positive breast cancer.

  Sledge GW. Sledge GW. Clin Adv Hematol Oncol. 2008 Feb;6(2):98-100. Clin Adv Hematol Oncol. 2008. PMID: 18347559 No abstract available.
• [Her2 positive breast cancer: practices].

  Campone M, Berton-Rigaud D, Bourbouloux E, Sophie S, Zanetti A, Frenel JS. Campone M, et al. Bull Cancer. 2011 Feb;98(2):154-63. Bull Cancer. 2011. PMID: 21591301 Review. French.
• [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].

  Yamashita T, Iwata K. Yamashita T, et al. Gan To Kagaku Ryoho. 2009 Dec;36(13):2551-4. Gan To Kagaku Ryoho. 2009. PMID: 20104676 Japanese. No abstract available.
• Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.

  Reed SD, Schulman KA. Reed SD, et al. Value Health. 2009 Jul-Aug;12(5):637-40. doi: 10.1111/j.1524-4733.2009.00564.x. Epub 2009 May 15. Value Health. 2009. PMID: 19473336 No abstract available.